Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
AcelRx Pharmaceuticals 0.48 0.004 0.90% -79.88%
Acura Pharmaceuticals 0.47 0.003 0.53% 125.00%
Endo International Ordinary Shares 3.23 0.05 1.57% -55.87%
Horizon Pharma 89.47 2.87 3.31% 24.56%
Jazz Pharmaceuticals 133.48 2.44 1.86% -19.61%
Eli Lilly 241.33 1.87 0.78% 16.26%
Nektar Therapeutics 10.90 -0.28 -2.50% -38.56%
Pacira 62.97 1.13 1.83% -8.58%
Perrigo 38.52 -0.09 -0.23% -13.42%
Supernus Pharmaceuticals 30.47 0.77 2.59% -1.46%
Teva Pharmaceutical Industries 8.50 -0.04 -0.41% -31.05%
Zogenix 25.96 0.03 0.10% 29.13%

Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.